Erythropoietin (EPO)-producing cells derived from human induced pluripotent stem (iPS) cells have been shown for the first time to be capable of successfully treating renal anemia in mice, Japanese researchers reported in the Sept. 27, 2017, edition of Science Translational Medicine.